Commitments (Details Textual) (USD $)	1 Months Ended				12 Months Ended						141 Months Ended		1 Months Ended	3 Months Ended				1 Months Ended	12 Months Ended			1 Months Ended		12 Months Ended													1 Months Ended		12 Months Ended		12 Months Ended
	Jan. 31, 2007	May 31, 2006	Feb. 28, 2006	Feb. 28, 2005	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2007	Dec. 31, 2004	Dec. 31, 2002	Dec. 31, 2013	Apr. 23, 2013	Feb. 28, 2014 Subsequent Event [Member]	Mar. 31, 2013 Phase III Clinical Trial [Member]	Dec. 31, 2012 Phase III Clinical Trial [Member]	Dec. 31, 2012 Phase II Clinical Trial [Member]	Jun. 30, 2012 Other Contractual Obligations [Member]	Feb. 28, 2014 Contract Research and Manufacturing Purchase Obligations [Member]	Dec. 31, 2012 Contract Research and Manufacturing Purchase Obligations [Member]	Dec. 31, 2011 Contract Research and Manufacturing Purchase Obligations [Member]	Dec. 31, 2013 Contract Research and Manufacturing Purchase Obligations [Member]	Dec. 31, 2006 Use Rights [Member] Development and Commercialization Agreement With Active Biotech [Member]	May 31, 2006 Use Rights [Member] Development and Commercialization Agreement With Active Biotech [Member]	Dec. 31, 2006 Use Rights [Member] Development and Commercialization Agreement With Active Biotech [Member]	Dec. 31, 2010 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2009 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2008 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2007 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2006 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2005 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2004 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2012 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2011 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2008 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2006 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2013 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Feb. 28, 2014 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member] Subsequent Event [Member]	Dec. 31, 2013 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member] N D A [Member]	Dec. 31, 2006 Finders Agreement [Member] Warrant [Member]	Dec. 31, 2013 Finders Agreement [Member] Warrant [Member]	Dec. 31, 2013 Facility Lease [Member]	Dec. 31, 2012 Facility Lease [Member]	Dec. 31, 2011 Facility Lease [Member]	Dec. 31, 2011 License Agreement [Member]
Commitment [Line Items]
Operating Leases, Rent Expense																																									$ 358,439	$ 358,439	$ 339,963
Lease Expiration Date																																									Mar. 11, 2016
Operating Leases, Future Minimum Payments Due																																									900,000
Operating Leases, Frequency Of Periodic Payment																																									monthly
Operating Leases, Periodic Payment																																									31,000
Percentage Of Increases In Annual Rent																																									3.00%
Security Deposit																																									38,000
Initial Payment Towards Use Of Rights As Per License Agreement																															150,000				100,000
Value Of Common Stock Issued During Period Towards Milestone Payment																												150,000	100,000	100,000
Common Stock Shares Issued During Period To wards Milestone Payment																											30,612	26,643
Fair Value Of Common Stock Issued During Period Towards Milestone Payment																											$ 4.90	$ 5.63
Milestone Payment Made During Period																									100,000	150,000	100,000						750,000	500,000
Potential Future Milestone Payments																									1,500,000											2,500,000		1,500,000		150,000
Common Stock Shares Issued During Period Towards Right To Use Intellectual Property																																			63,131
Fair Value Of Common Stock Issued During Period Towards Right To Use Intellectual Property																																			$ 4.35
Value Of Common Stock Issued During Period Towards Right To Use Intellectual Property																																			274,621
Research and Development Expense (Excluding Acquired in Process Cost)																			1,200,000	3,800,000												3,100,000												750,000
Warrants issued to purchase common stock	0	250,000	716,666	105,516					483,701
Common stock warrants, purchase price		$ 4.31	$ 3.30	$ 2.62					$ 2.88
Fair Value Of Warrants Granted	433,750		705,000	26,700					14,400
Weighted-average risk-free interest rate					0.69%	0.74%	1.83%																																4.79%
Weighted-average expected life of options					4 years 4 months 24 days	5 years	5 years																																3 years
Expected dividend yield					0.00%	0.00%	0.00%																																0.00%
Weighted-average expected volatility					105.48%	89.73%	87.82%																																66.01%
Research and development					10,367,757	16,744,423	37,270,138	600,000			172,872,603			1,600,000				4,600,000		7,200,000		1,000,000	1,000,000
Additional Research And Development Expense																								300,000
Decrease In Research and Development Expense															900,000	500,000
Increase In Research and Development Expense														500,000
Sales and marketing					1,089,053	7,221,800	8,067,709				25,335,429						100,000
Purchase Commitment, Remaining Minimum Amount Committed																					23,600,000
Commitment And Contingencies Bonus Payments Obligation					1,300,000						1,300,000
Beneficial Ownership Percentage												50.00%
Payments for Royalties																																					1,500,000
Retention Bonus Plans bonus approved													$ 1,300,000